The partial ineffectiveness and side effects of inflammatory bowel disease (IBD) current therapies drive basic research to look for new therapeutic target in order to develop new drug lead. Considering the pivotal role played by toll-like receptors (TLRs) in gut inflammation, we evaluate here the therapeutic effect of the synthetic glycolipid TLR4 antagonist FP7.
Facchini, F.a., Di Fusco, D., Barresi, S., Luraghi, A., Minotti, A., Granucci, F., et al. (2020). Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 76(3), 409-418 [10.1007/s00228-019-02799-7].
Effect of chemical modulation of toll-like receptor 4 in an animal model of ulcerative colitis
Monteleone G.Membro del Collaboration Group
;Monteleone I.
2020-01-25
Abstract
The partial ineffectiveness and side effects of inflammatory bowel disease (IBD) current therapies drive basic research to look for new therapeutic target in order to develop new drug lead. Considering the pivotal role played by toll-like receptors (TLRs) in gut inflammation, we evaluate here the therapeutic effect of the synthetic glycolipid TLR4 antagonist FP7.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
